
    
      Study Design:

      Prospective, multi-center, single-arm, open-label, Phase 3 clinical study to 3 years with
      extension up to 5 years

      Number of Subjects:

      Approximately 1,605 subjects will be enrolled into the study

      Study Population:

      Post-menarcheal, pre-menopausal women up to age 45 years, who are at risk for pregnancy and
      who desire a long-term intrauterine contraceptive for birth control will be eligible for this
      study.

      Primary Endpoint:

      The primary endpoint is the contraceptive efficacy through 3 years of use, as assessed by the
      Pearl Index.

      Secondary endpoints:

      Contraceptive Efficacy:

        -  Pearl Index at Years 4 and 5, as well as cumulatively through Years 4 and 5.

        -  Pregnancy percentage by life table analysis (Kaplan-Meier) at Years 1, 2, 3, 4 and 5

      Study drug placement:

        -  Ease of VeraCept placement

        -  Placement success

      Safety:

        -  Serious adverse events (SAEs)

        -  Adverse events (AEs)

        -  Pelvic infection (pelvic inflammatory disease (PID) or endometritis)

        -  Ectopic pregnancies

        -  Uterine perforations

        -  Dysmenorrhea

        -  Abdominal pain

        -  Expulsion rates at Years 1, 2, 3, 4 and 5

      Tolerability:

        -  Bleeding and spotting patterns

        -  Insertion pain assessed immediately after insertion

        -  Continuation rates at Years 1, 2, 3, 4 and 5

        -  Reasons for discontinuation

      Return to fertility

      ‚óè Pregnancy rate in subjects who request VeraCept removal specifically to become pregnant.
      Subjects who desire pregnancy after having VeraCept removed will be followed for either 1
      year, until they decide to no longer try to conceive or they become pregnant, whichever comes
      first.
    
  